Monitor for insider selling or short interest changes post-offering; assess clinical progress of Varseta-M in metastatic colorectal cancer as the key value driver. The stock may experience near-term pressure due to dilution despite the cash infusion.
CTMX drugs
CTMX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $4.40entry
- T+1 · 8mo ago +8.64%α +8.90% · $4.78
- T+5 · 8mo ago −4.09%α −3.38% · $4.22
- T+20 · 7mo ago +11.14%α +5.09% · $4.89
- T+60 · 5mo ago −32.27%α −43.80% · $2.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30 per share, raising $250 million in gross proceeds. The company plans to use the funds primarily for the development of its lead asset Varseta-M and other pipeline programs, with a 30-day over-allotment option for up to an additional 7,075,471 shares.
Key Financial Metrics
Key Facts
- CytomX raised $250 million in gross proceeds through a public offering.
- Offering includes 45,990,567 common shares and pre-funded warrants for 1,179,245 shares, priced at $5.30 per share.
- Underwriters have a 30-day option to purchase up to an additional 7,075,471 shares.
- Proceeds will fund development of Varseta-M (CX-2051) and other pipeline assets, plus general corporate purposes.
- Closing expected on March 19, 2026, subject to customary conditions.
Financial Impact
$250 million gross proceeds, with potential for up to $38.5 million more if over-allotment is exercised (total ~$288.5M gross).
Risk Factors
- Significant shareholder dilution from issuance of nearly 47.2 million shares and warrants (pre- and post-over-allotment).
- Forward-looking use of proceeds with no guaranteed clinical or commercial success.
- Biotech market sensitivity to capital raises in absence of near-term catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257862 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Viewing Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers